Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients and Clinical/Biological Feature Correlations: Impact on the Practice

Fabi, Alessandra; Moscetti, Luca; Ciccarese, Mariangela; Caramanti, Miriam; Salesi, Nello; Verde, Nicla La; Russillo, Michelangelo; Generali, Daniele; Scandurra, Giuseppa; Vari, Sabrina; Pacetti, Umberto; Cognetti, Francesco; Giannarelli, Diana

doi:10.2217/fon.14.271

Cited by 19 publications

(27 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of note, 52% of the patients had already received vinorelbine, and all the subjects had been previously treated with a taxane-based chemotherapy, agents known for causing peripheral neuropathy [31]. These findings could suggest that eribulin may not aggravate peripheral neuropathy toxicity in patients pretreated with neurotoxic drugs, as reported by Fabi et al [26]. Moreover, no differences in toxicity were observed between young and elderly patients, considering that 36% of the patients were 65 years or older.…”

Section: Discussionmentioning

confidence: 56%

Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study

et al. 2018

View full text Add to dashboard Cite

Objectives: The aim of this study was to investigate efficacy and safety of eribulin in heavily pretreated patients with advanced breast cancer (BC) in a real-life setting. Methods: This retrospective monocentric study included patients with HER-2-negative metastatic BC, pretreated with anthracyclines and taxanes, who were referred to the Oncology Department of Spedali Civili of Brescia from May 2012 to April 2017. Patients received the same dose of eribulin as that used in the EMBRACE trial: 1.4 mg/m² on days 1 and 8 every 21 days. Results: In a total of 53 patients, 32% obtained a partial response, 11% a stable disease, and 43% a clinical benefit (CB). After a median follow-up of 36 months, median progression-free survival (PFS) was 4.7 months and median overall survival (OS) 13.53 months. Median PFS was significantly longer in patients who reported a CB compared to those with no CB, while survival outcomes (PFS and OS) were better in patients who received > 6 cycles of eribulin. Eribulin showed a good tolerability profile with acceptable toxicities, similar to those reported in EMBRACE. Conclusions: Our experience in a real-world setting confirms the activity, efficacy, and good tolerability profile of eribulin in heavily pretreated BC patients.

show abstract

Section: Discussionmentioning

confidence: 56%

Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The toxicity profile was favourable and, as expected, neutropaenia and neurotoxicity were the most common adverse events. 24 In conclusion, with the limitations due to the observational nature of our findings, eribulin once again was shown to be an effective and safe therapeutic option for second and further lines of treatment in patients with advanced BC.…”

Section: Discussionmentioning

confidence: 62%

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

et al. 2017

View full text Add to dashboard Cite

BackgroundOn the basis of the results of two pivotal phase III clinical trials, eribulin mesylate is currently approved in EU for the treatment of advanced breast cancer (aBC) in patients who have previously received an anthracycline and a taxane in either the adjuvant or the metastatic setting, and at least one chemotherapeutic regimen for metastatic disease.MethodsIn our study, we investigated the efficacy and tolerability of eribulin as second or further line chemotherapy in 137 women affected by aBC.ResultsEribulin as monotherapy provided benefit in terms of progression-free survival (PFS), response rate (RR) and disease control rate (DCR) independently of its use as second or late-line therapy. The overall RR and DCR were 17.5% and 64%, respectively. In particular, DCR and overall RR were 50% and 13.6%, 65.4% and 21.1%, 70.4% and 14.8% and 66.7% and 16.7% in second, third, fourth and further lines of treatment, respectively. Median PFS (mPFS) according to the line of therapy was 5.7, 6.3, 4.5 and 4.0 months in patients treated with eribulin in second, third, fourth and over the fourth line, respectively. No significant difference in terms of mPFS was found between the various BC subtypes. Overall, eribulin resulted safe and most adverse events were of grade 1 or 2 and easily manageable. Grades 3–4 toxicities were neutropaenia and neurotoxicity.ConclusionsWith the limitations due to the observational nature of our findings, eribulin was shown to be an effective and safe therapeutic option in heavily pretreated patients with aBC.

show abstract

“…A number of studies and case reports have documented its effectiveness and safety in a field-practice scenario [7][8][9][10][11][12][13].…”

Section: Discussionmentioning

confidence: 99%

Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report

Leo¹,

Caputo²,

Sarno³

et al. 2015

Future Oncol.

View full text Add to dashboard Cite

In this short paper, we report our experience with eribulin mesylate in a heavily pretreated breast cancer patient with multiple bone metastases. The patient had been treated with doxorubicin, cyclophosphamide, methotrexate, fluorouracil, tamoxifen, letrozole, LH-RH analogs, fulvestrant, bevacizumab and paclitaxel and liposomal doxorubicin. In November 2013 treatment with eribulin ready to use solution (1.23 mg/m(2) days 1 and 8 of a 21-day cycle) was started and administered for a total of 14 courses. After six cycles of eribulin, evaluation with MRI showed a marked decrease in neoplastic involvement and replacement of osteolytic lesions with osteoblastic ones. No unexpected acute toxicity was observed. Although with all the limitations of any anecdotal report, our experience documents the efficacy and safety of eribulin in this difficult-to-treat patient who had been treated with multiple lines of chemotherapy.

show abstract

Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients and Clinical/Biological Feature Correlations: Impact on the Practice

Abstract: Our study confirms the effectiveness of eribulin mesylate in the treatment of patients with metastatic breast cancer and two or more lines of chemotherapy, in particular in the good disease control at the different metastatic sites.

Cited by 19 publications

References 18 publications

Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study

Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report

Contact Info

Product

Resources

About